Literature DB >> 12665330

Estrogen and progesterone receptor assay in paraffin-embedded breast cancer--reproducibility of assessment.

Gunilla Chebil1, Pär-Ola Bendahl, Mårten Fernö.   

Abstract

Immunohistochemical (IHC) assays are routinely used for determining the estrogen receptor (ER) and progesterone receptor (PgR) status of women with breast cancer. The present knowledge of reproducibility of the subjective IHC assessment is limited. The purpose of this study was to evaluate the interobserver reproducibility in IHC assessment of 127 (ER) and 126 (PgR) cases of primary breast cancer. The slides were independently re-assessed by 22 pathologists from nine hospitals. A simple assessment protocol was used with a cut-off value > 10% stained nuclei, regardless of staining intensity. The concordance was high, with a kappa value of 0.78 for ER and 0.72 for PgR. Since some of the 22 pathologists considered one or several sections to be inevaluable, the evaluation comprised three groups (< or = 10% vs. > 10% vs. not evaluated). Although the percentage of positive cases varied among the 22 pathologists (ER: 57%-79%; PgR: 41%-66%), the overall concordance was good for both ER and PgR (kappa = 0.78 and 0.72, respectively). A further improvement in concordance should be possible to achieve through training.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12665330     DOI: 10.1080/02841860300672

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  10 in total

1.  A novel animal model for locally advanced breast cancer.

Authors:  Maria V Bogachek; Jung Min Park; James P De Andrade; Mikhail V Kulak; Jeffrey R White; Tong Wu; Philip M Spanheimer; Thomas B Bair; Alicia K Olivier; Ronald J Weigel
Journal:  Ann Surg Oncol       Date:  2014-10-18       Impact factor: 5.344

2.  A systematic review of datasets that can help elucidate relationships among gene expression, race, and immunohistochemistry-defined subtypes in breast cancer.

Authors:  Ifeanyichukwu O Nwosu; Stephen R Piccolo
Journal:  Cancer Biol Ther       Date:  2021-08-19       Impact factor: 4.875

3.  Technical note on the validation of a semi-automated image analysis software application for estrogen and progesterone receptor detection in breast cancer.

Authors:  László Krecsák; Tamás Micsik; Gábor Kiszler; Tibor Krenács; Dániel Szabó; Viktor Jónás; Gergely Császár; László Czuni; Péter Gurzó; Levente Ficsor; Béla Molnár
Journal:  Diagn Pathol       Date:  2011-01-18       Impact factor: 2.644

4.  Evaluation of the progesterone receptor status in breast cancer using three different antibodies: a comparison by Allred score system.

Authors:  Renata Dalmaschio Daltoé; Klesia Pirola Madeira; Alex Assis de Carvalho; Lucas Cunha Dias de Rezende; Ian Victor Silva; Leticia Batista Azevedo Rangel
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

5.  Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection.

Authors:  Trine Tramm; Guido Hennig; Marianne Kyndi; Jan Alsner; Flemming Brandt Sørensen; Simen Myhre; Therese Sørlie; Jens Overgaard
Journal:  Virchows Arch       Date:  2013-10-08       Impact factor: 4.064

6.  Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study.

Authors:  Akihiko Ozaki; Shuhei Nomura; Claire Leppold; Masaharu Tsubokura; Tetsuya Tanimoto; Takeru Yokota; Shigehira Saji; Toyoaki Sawano; Manabu Tsukada; Tomohiro Morita; Sae Ochi; Shigeaki Kato; Masahiro Kami; Tsuyoshi Nemoto; Yukio Kanazawa; Hiromichi Ohira
Journal:  BMC Cancer       Date:  2017-06-19       Impact factor: 4.430

7.  Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens.

Authors:  Slavica Janeva; Toshima Z Parris; Salmir Nasic; Shahin De Lara; Karolina Larsson; Riccardo A Audisio; Roger Olofsson Bagge; Anikó Kovács
Journal:  BMC Cancer       Date:  2021-04-21       Impact factor: 4.430

8.  CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.

Authors:  H Jernström; E Bågeman; C Rose; P-E Jönsson; C Ingvar
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

9.  Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.

Authors:  D Mouttet; M Laé; M Caly; D Gentien; S Carpentier; H Peyro-Saint-Paul; A Vincent-Salomon; R Rouzier; B Sigal-Zafrani; X Sastre-Garau; F Reyal
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

10.  Concordance between Immunohistochemistry and Microarray Gene Expression Profiling for Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Statuses in Breast Cancer Patients in Lebanon.

Authors:  Ghina B Fakhri; Reem S Akel; Maya K Khalil; Deborah A Mukherji; Fouad I Boulos; Arafat H Tfayli
Journal:  Int J Breast Cancer       Date:  2018-05-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.